NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

Download a CSV of all Patent records.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset Search to show all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-099-2014-0-GB-21 MESOTHELIN-TARGETED CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF GB EP 15803100.5 Issued
NCI E-099-2014-0-EP-06 MESOTHELIN-TARGETED CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF EP National Stage 15803100.5 Issued
NCI E-099-2014-0-PCT-02 Mesothelin-targeted chimeric antigen receptors and uses thereof PCT PCT PCT/US2015/034552 Expired
NCI E-099-2014-0-CN-05 MESOTHELIN-TARGETED CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF CN National Stage 201580042449.7 Pending
NCI E-099-2014-0-JP-07 MESOTHELIN-TARGETED CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF JP National Stage 2016-571020 Abandoned
NCI E-099-2014-0-CA-04 MESOTHELIN-TARGETED CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF CA National Stage 2950763 Pending
NCI E-180-2015-0-US-01 Anti-Mutated Kras T Cell Receptors US 62/171,321 Abandoned
NCATS E-187-2009-2-US-06 OXADIAZOLO[3,2-A]PYRIMIDINES AND THIADIAZOLO[3,2-A]PYRIMIDINES US DIV 14/730,707 9532989 Abandoned PDF
NIAAA E-282-2012-1-US-01 CANNABINOID RECEPTOR MEDIATING COMPOUNDS US 62/171,179 Abandoned
NIAID E-130-2015-0-US-01 NEUTRALIZING ANTIBODIES TO HIV-1 ENV AND THEIR USE US 62/170,558 Abandoned
NEI E-248-2012-0-EP-05 Method of Reducing Adverse Effects in a Cancer Patient Undergoing Treatment with a MEK Inhibitor EP National Stage 13792162.3 Issued
NEI E-248-2012-0-IE-10 Method of Reducing Adverse Effects in a Cancer Patient Undergoing Treatment with a MEK Inhibitor IE EP 13792162.3 Issued
NEI E-248-2012-0-GB-09 Method of Reducing Adverse Effects in a Cancer Patient Undergoing Treatment with a MEK Inhibitor GB EP 13792162.3 Issued
NEI E-248-2012-0-DE-07 Method of Reducing Adverse Effects in a Cancer Patient Undergoing Treatment with a MEK Inhibitor DE EP 13792162.3 Issued
NEI E-248-2012-0-FR-08 Method of Reducing Adverse Effects in a Cancer Patient Undergoing Treatment with a MEK Inhibitor FR EP 13792162.3 Issued
NCI E-042-2014-0-KR-10 Chimeric Antigen Receptors Targeting CD-19 KR National Stage 10-2016-7036828 Issued
NCI E-042-2014-0-IN-08 CHIMERIC ANTIGEN RECEPTORS TARGETING CD 19 IN National Stage 201647041047 Issued
NCI E-042-2014-0-SG-14 Chimeric Antigen Receptors Targeting CD-19 SG National Stage 11201609960Q Issued
NCI E-042-2014-0-SA-13 Chimeric Antigen Receptors Targeting CD-19 SA National Stage 516380406 Issued
NCI E-042-2014-0-CN-05 Chimeric Antigen Receptors Targeting CD-19 CN National Stage 201580033802.5 Issued
NCI E-042-2014-0-MX-11 Chimeric Antigen Receptors Targeting CD-19 MX National Stage MX/a/2016/015834 Issued
NCI E-042-2014-0-AU-03 Chimeric Antigen Receptors Targeting CD-19 AU National Stage 2015270912 Issued
NCI E-042-2014-0-JP-09 Chimeric Antigen Receptors Targeting CD-19 JP National Stage 2016-571017 Issued
NCI E-042-2014-0-IT-23 Chimeric Antigen Receptors Targeting CD-19 IT EP 15729304.4 Issued
NCI E-042-2014-0-IE-24 Chimeric Antigen Receptors Targeting CD-19 IE EP 15729304.4 Issued
NCI E-042-2014-0-FR-21 Chimeric Antigen Receptors Targeting CD-19 FR EP 15729304.4 Issued
NCI E-042-2014-0-DE-19 Chimeric Antigen Receptors Targeting CD-19 DE EP 15729304.4 Issued
NCI E-042-2014-0-ES-20 Chimeric Antigen Receptors Targeting CD-19 ES EP 15729304.4 Issued
NCI E-042-2014-0-GB-22 Chimeric Antigen Receptors Targeting CD-19 GB EP 15729304.4 Issued
NCI E-042-2014-0-US-15 Chimeric Antigen Receptors Targeting CD-19 US National Stage 15/315,533 10287350 Issued PDF
NCI E-042-2014-0-PCT-02 Chimeric Antigen Receptors Targeting CD-19 PCT PCT PCT/US2015/033473 Expired
NCI E-124-2011-0-US-03 Anti-podoplanin Antibodies And Methods Of Use US CON 14/726,959 Abandoned
NCI E-042-2014-0-CA-04 Chimeric Antigen Receptors Targeting CD-19 CA National Stage 2951045 Pending
NCI E-176-2014-0-BR-04 Anti-Human Papillomavirus 16 E7 T Cell Receptors BR National Stage BR112016027805-4 Issued
NCI E-176-2014-0-CN-06 Anti-Human Papillomavirus 16 E7 T Cell Receptors CN National Stage 201580031789.X Issued
NCI E-176-2014-0-SA-12 Anti-Human Papillomavirus 16 E7 T Cell Receptors SA National Stage 516380394 Issued
NCI E-176-2014-0-MX-11 Anti-Human Papillomavirus 16 E7 T Cell Receptors MX National Stage MX/a/2016/015383 Issued
NCI E-176-2014-0-JP-09 Anti-Human Papillomavirus 16 E7 T Cell Receptors JP National Stage 2017-515021 Issued
NCI E-176-2014-0-AU-03 Anti-Human Papillomavirus 16 E7 T Cell Receptors AU National Stage 2015266818 Issued
NCI E-176-2014-0-AT-19 Anti-Human Papillomavirus 16 E7 T Cell Receptors AT EP 15729004.0 Issued
NCI E-176-2014-0-AL-18 Anti-Human Papillomavirus 16 E7 T Cell Receptors AL EP 15729004.0 Issued
NCI E-176-2014-0-BE-20 Anti-Human Papillomavirus 16 E7 T Cell Receptors BE EP 15729004.0 Issued
NCI E-176-2014-0-LT-38 Anti-Human Papillomavirus 16 E7 T Cell Receptors LT EP 15729004.0 Issued
NCI E-176-2014-0-LU-39 Anti-Human Papillomavirus 16 E7 T Cell Receptors LU EP 15729004.0 Issued
NCI E-176-2014-0-LV-40 Anti-Human Papillomavirus 16 E7 T Cell Receptors LV EP 15729004.0 Issued
NCI E-176-2014-0-IT-37 Anti-Human Papillomavirus 16 E7 T Cell Receptors IT EP 15729004.0 Issued
NCI E-176-2014-0-SE-48 Anti-Human Papillomavirus 16 E7 T Cell Receptors SE EP 15729004.0 Issued
NCI E-176-2014-0-CH-22 Anti-Human Papillomavirus 16 E7 T Cell Receptors CH EP 15729004.0 Issued
NCI E-176-2014-0-TR-52 Anti-Human Papillomavirus 16 E7 T Cell Receptors TR EP 15729004.0 Issued
NCI E-176-2014-0-ES-28 Anti-Human Papillomavirus 16 E7 T Cell Receptors ES EP 15729004.0 Issued